Page last updated: 2024-12-06

trausabun

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

melitracene: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25382
CHEMBL ID110094
CHEBI ID135214
SCHEMBL ID48975
MeSH IDM0046427

Synonyms (64)

Synonym
melitracen [inn]
n,n,10,10-tetramethyl-delta(sup 9(10),gamma)-anthracenepropylamine
thymeol
9-(3-dimetilaminopropyliden)-10,10-dimetil-9,10-diidroanthracene [italian]
dixeran
u-24973
einecs 225-858-5
melitracene [inn-french]
melitracenum [inn-latin]
delta-(sup 9(10),gamma)-anthracenepropylamine, n,n,10,10-tetramethyl-
brn 1980107
melitraceno [inn-spanish]
trausabun
melitracene
1-propanamine, 3-(10,10-dimethyl-9(10h)-anthracenylidene)-n,n-dimethyl-
melitracen
n,n,10, 10-tetramethyl-.delta.(sup9(10h)),.gamma.-anthracenepropylamine hydrochloride
u-24,973a (*hydrochloride*)
.delta.9(10h), .gamma.-anthracenepropylamine, n,n,10,10-tetramethyl-, hydrochloride
melitracene (*hydrochloride*)
3-(10,10-dimethyl-9-anthrylidene)-n,n-dimethyl-propan-1-amine
n 7001 (*hydrochloride*)
melitracen (usan)(*hydrochloride*)
3-(10,10-dimethyl-9(10h)-anthracenylidene)-n,n-dimethyl-1-propanamine
n-(3-(10,10-dimethyl-9(10h)-anthracenylidene)propyl)-n,n-dimethylamine
thymeo (*hydrochloride*)
u 24973 (*hydrochloride*)
n,n,10, 10-tetramethyl-.delta.9(10h), .gamma.-anthracenepropylamine hydrochloride
n,n,10,10-tetramethyl-.delta.9(10h), .gamma.-anthracenepropylamine, hydrochloride
1-propanamine, 3-(10, 10-dimethyl-9(10h)-anthracenylidene)-n,n-dimethyl-, hydrochloride
1-propanamine, 3-(10, 10-dimethyl-9(10h)-anthracenylidene)-n,n-dimethyl-
{9-[(3-dimethylamino)propylidene]-10,10-dimethyl-9,} 10-dihydroanthracene hydrochloride
.delta.(sup9(10h)),.gamma.-anthracenepropylamine, n,n,10, 10-tetramethyl-, hydrochloride
NCIOPEN2_008949
CHEBI:135214
adelax
CHEMBL110094
melitracen (inn)
adelax (tn)
D08171
5118-29-6
3-(10,10-dimethylanthracen-9-ylidene)-n,n-dimethylpropan-1-amine
melitraceno
9-(3-dimetilaminopropyliden)-10,10-dimetil-9,10-diidroanthracene
melitracenum
unii-q7t0y1109z
q7t0y1109z ,
bdbm112783
us8629135, sw-14
AKOS025311490
SCHEMBL48975
melitracen [mi]
melitracen [who-dd]
DTXSID4048274
GWWLWDURRGNSRS-UHFFFAOYSA-N
3-(10,10-dimethylanthracen-9(10h)-ylidene)-n,n-dimethylpropan-1-amine
HY-121778
Q411251
DB13384
1-propanamine, 3-(10,10-dimethyl-9(10h)-anthracenylidene)-n,n-dimethyl- (9ci)
AMY32528
A855294
CS-0083286
[3-(10,10-dimethyl-9,10-dihydroanthracen-9-ylidene)propyl]dimethylamine

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Many pharmaceuticals include highly potent active pharmaceutical ingredients (API), which only require a small dosage to obtain the desired therapeutic effect."( Fluorescence spectroscopy in process analytical technology (PAT): simultaneous quantification of two active pharmaceutical ingredients in a tablet formulation.
Allesø, M; Engelsen, SB; Rinnan, Å; Warnecke, S, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
anthracenesCompounds containing an anthracene skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID504865
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.41250.035520.977089.1251AID504332
gemininHomo sapiens (human)Potency31.67680.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID25866Protonation constant of the compound.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID26538log K was measured potentiometrically in Brij35 medium1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID23708Partition coefficient (logP)1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID26300log P values determined at pH 7.41999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (38.46)18.7374
1990's2 (15.38)18.2507
2000's3 (23.08)29.6817
2010's2 (15.38)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (13.33%)4.05%
Observational0 (0.00%)0.25%
Other10 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]